Single-nucleotide polymorphisms in the UDP-glucuronosyltransferase 1A-3' untranslated region are associated with atazanavir-induced nephrolithiasis in patients with HIV-1 infection: a pharmacogenetic study
Author(s) -
Takeshi Nishijima,
K. Tsuchiya,
Noriko Tanaka,
Akane Joya,
Yohei Hamada,
Daiki Mizushima,
Toshio Aoki,
Kôji Watanabe,
Ei Kinai,
Hirokazu Honda,
Hirohisa Yazaki,
Junko Tanuma,
K. Tsukada,
Katsuji Teruya,
Yoshimi Kikuchi,
Shinichi Oka,
Hiroyuki Gatanaga
Publication year - 2014
Publication title -
journal of antimicrobial chemotherapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.124
H-Index - 194
eISSN - 1460-2091
pISSN - 0305-7453
DOI - 10.1093/jac/dku304
Subject(s) - atazanavir , pharmacogenetics , single nucleotide polymorphism , ugt2b7 , genetics , biology , virology , glucuronosyltransferase , genotype , medicine , human immunodeficiency virus (hiv) , pharmacology , gene , glucuronidation , antiretroviral therapy , viral load , in vitro , microsome
Ritonavir-boosted atazanavir (atazanavir/ritonavir) is a widely used antiretroviral drug, though it can potentially cause nephrolithiasis. The aim of this study was to determine the relationship between polymorphisms in genes encoding proteins involved in metabolism and transportation of atazanavir, and atazanavir/ritonavir-induced nephrolithiasis in HIV-1-infected patients treated with atazanavir/ritonavir.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom